More Questions About IV Drug

Another clinical trial raises concerns about the efficacy and safety of a common intravenous treatment for patients that have lost large amounts of blood.

Bob Grant
Bob Grant

Bob started with The Scientist as a staff writer in 2007. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism...

View full profile.


Learn about our editorial policies.

Oct 17, 2012

Wikimedia, MichaelberryHydroxyethyl starch (HES), which is typically given to emergency room patients that have lost a lot of blood or are suffering systemic infection, is under the microscope again after recent clinical trial results indicate that the treatment may do more harm than good. The new data, published yesterday in The New England Journal of Medicine, indicated that of more than 6,600 patients treated with HES in intensive care units in Australia and New Zealand, 18 percent treated with HES died within 90 days compared to 17 percent treated with simple saline solution. Though that result isn't statistically significant, patients receiving HES were also more likely to require kidney replacement than patients receiving saline, and HES-treated patients experienced significantly higher rates of adverse events such as itching and bleeding.

"We need to consider more closely what fluid we give to specific patients and how much," lead author John...

These latest data add to a body of literature that suggests problems with HES treatment. This past June, a Danish study suggested that patients receiving HES were significantly more likely to die within 90 days or to require kidney transplants than those getting an alternative solution called Ringer's acetate. That study kicked up controversy over a misplaced decimal point, which was subsequently corrected, and led the US Food and Drug Administration to consider discontinuing HES treatment for infection patients.

Interested in reading more?

More Questions About IV Drug

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?